- Thursday, September 6, 10:20 a.m. EDT -
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced that Walter C.
Herlihy, Ph.D., President and Chief Executive Officer, will be
presenting at the upcoming Stifel Nicolaus Healthcare Conference in
Boston. Dr. Herlihy will provide a corporate update and discuss the
Company’s recent decision to focus corporate strategy on the growth of
its bioprocessing business. The Repligen presentation is scheduled for
Thursday, September 6, 2012 at 10:20 a.m. EDT.
A live webcast and subsequent archived replay of the presentation will
be available through the Investors section of Repligen’s corporate
website at www.repligen.com.
To access the live webcast, please log on through the Company’s website
approximately 15 minutes prior to the presentation.
About Repligen Corporation
Repligen Corporation is a life sciences company focused on the
development, production and commercialization of products used in the
process of manufacturing biological drugs. Our bioprocessing products
are sold to major life sciences and biopharmaceutical companies
worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to manufacture monoclonal antibody-based therapeutics. We
also supply several growth factor products used to increase cell culture
productivity in biomanufacturing. In the burgeoning area of disposable
biomanufacturing technologies, we have developed and market a series of
OPUS™ (Open Platform User Specified) single-use chromatography columns
used in the biologics purification process. In addition to our core
bioprocessing business, we have a portfolio of clinical-stage partnering
assets, including two central nervous system orphan drug candidates and
a pancreatic imaging agent in Phase 3 development. Repligen’s corporate
headquarters are located in Waltham, MA, USA; we have an additional
manufacturing facility in Lund, Sweden. For more information, please
visit our website at www.repligen.com.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation